TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31884854
Drug: Canakinumab 50
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 50 mg, 150 mg, 300 mg
Study: 31124588
Drug: Oral immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunoglobulin supplementation (20 g in milk twice daily for 14 days)
Study: 31124588
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g of a product with similar nutritional value but without immunoglobulins in milk, twice daily for 14 days)
Study: 23301502
Drug: Ganciclovir (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (2.5 mg/kg intravenously)
Study: 23301502
Drug: Valganciclovir (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (1800 mg orally)
Study: 19339324
Drug: Recovery Workbook
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery Workbook training in addition to usual treatment (N=16)
Study: 19339324
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control group, N=17)
Study: 9725552
Drug: Terfenadine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine with atorvastatin
Study: 355024
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injections)
Study: 11369067
Drug: Conventional computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional computed tomography-based treatment planning (Group A, n=11)
Study: 30519531
Drug: Therapist-supported internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-supported internet-based cognitive behavioural therapy (ICBT)
Study: 15610950
Drug: ziprasidone (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone (80-120 mg/day)
Study: 15610950
Drug: haloperidol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (5-20 mg/day)
Study: 12378660
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion 3-6 mg kg‐1 h‐1
Study: 12378660
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion 10-30 micrograms kg‐1 h‐1
Study: 10210379
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of epirubicin (1 mg/ml, 50 mg/50 ml solution)
Study: 10210379
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of epirubicin (2 mg/ml, 100 mg/50 ml solution)
Study: 2702064
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 6-mercaptopurine (6-MP) in fasting state
Study: 2702064
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 6-mercaptopurine (6-MP) with breakfast
Study: 178197
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of propantheline bromide
Study: 31774299
Drug: HELP diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HELP diet with 400 mg/kg Res
Study: 31774299
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet with 400 mg/kg Res
Study: 24517156
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (denosumab + teriparatide)
Study: 17618813
Drug: Arteriovenous fistula
Normalized name: Cassia fistula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arteriovenous fistula (AVF) at the wrist for chemotherapy administration
Study: 17618813
Drug: Chemotherapy through
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy through peripheral veins without AVF (historical controls)
Study: 15755861
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (2 mg 17beta-estradiol/d)
Study: 31273513
Drug: Rituximab-based immuno-chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-based immuno-chemotherapy
Study: 25162217
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EFV in combination with emtricitabine/tenofovir
Study: 25162217
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg EFV in combination with emtricitabine/tenofovir
Study: 19033020
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg sodium selenite daily
Study: 19033020
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg sodium selenite daily
Study: 17066642
Drug: Rough-surfaced microthreaded
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surfaced microthreaded neck implants (Oneplant)
Study: 17066642
Drug: Rough-surfaced neck
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surfaced neck implants (Stage 1)
Study: 17066642
Drug: Machined neck
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined neck implants (Ankylos)
Study: 12895208
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline bitartrate (50 mg/kg/day)
Study: 10875609
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor therapy
Study: 9437195
Drug: Alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (50 mg daily) and Beta-carotene (20 mg daily)
Study: 3669070
Drug: Prompt format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt format (monthly reminders to self-examine)
Study: 31542368
Drug: Intranasal ITN
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ITN administration
Study: 31542368
Drug: Extranasal ITN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extranasal ITN administration (control)
Study: 31542368
Drug: Intranasal ITN
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ITN administration (Study 2)
Study: 29735394
Drug: Dorzagliatin 75
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 75 mg once daily
Study: 29735394
Drug: Dorzagliatin 100
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 100 mg once daily
Study: 29735394
Drug: Dorzagliatin 50
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 50 mg twice daily
Study: 29735394
Drug: Dorzagliatin 75
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 75 mg twice daily
Study: 23422767
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (7 units) administered subcutaneously
Study: 23422767
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test with insulin administration
Study: 23422767
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test without insulin administration
Study: 12139118
Drug: 3-4 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Study: 12139118
Drug: 8-10 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-10 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Study: 12139118
Drug: 16-18 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-18 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Study: 2502938
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK 500 mg four times daily for five days
Study: 2502938
Drug: Placebo four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo four times daily for five days
Study: 2502938
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK 500 mg (compliance considered)
Study: 28872381
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential pneumatic compression (ISPC)
Study: 17846141
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg orally four times a day for 7 days after incision and drainage
Study: 15221421
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch 5% for 1 week
Study: 15221421
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 12 h daily
Study: 12516939
Drug: Valaciclovir suspension
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir suspension 10 mg/kg
Study: 12516939
Drug: Valaciclovir suspension
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir suspension 20 mg/kg
Study: 12516939
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg tablets
Study: 9828736
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg/dose four times daily (n = 18)
Study: 7862849
Drug: Ephedrine (37.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (37.5-75 mg)
Study: 2688064
Drug: naproxen, 750
Normalized name: Naproxen, 750 mg (as sodium) oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen, 750 mg/day for 1 week
Study: 2688064
Drug: oxindanac, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxindanac, 600 mg/day for 1 week
Study: 23064293
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg oral ephedrine
Study: 21641868
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus zoledronic acid (20 mg per day + 4 mg every 6 months)
Study: 21641868
Drug: Anastrozole plus
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole plus zoledronic acid (1 mg per day + 4 mg every 6 months)
Study: 21641868
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (20 mg per day)
Study: 21641868
Drug: Anastrozole alone
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole alone (1 mg per day)
Study: 21641868
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg every 6 months)
Study: 19124803
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (fluorouracil-based therapy)
Study: 16942532
Drug: Flexible-dose vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose vardenafil (5-20 mg)
Study: 15254851
Drug: Valerian/hop extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian/hop extract (2 tablets)
Study: 15254851
Drug: Valerian/hop extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian/hop extract (6 tablets)
Study: 9537864
Drug: Metadoxine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine (1500 mg/day)
Study: 30528472
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg orally once daily for 6 months
Study: 27363424
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 100 mg/piece
Study: 25693137
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 0.5% isobaric bupivacaine (initial dose) adjusted by 0.1 ml based on previous outcomes
Study: 24167059
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 7.5 mg/kg/day
Study: 17223806
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (30 microg.kg‐1)
Study: 17223806
Drug: Warming with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming with forced-air and intravenous midazolam (30 microg.kg‐1)
Study: 17223806
Drug: Passive insulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive insulation and intravenous midazolam (30 microg.kg‐1)
Study: 15226332
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy (no AC)
Study: 11476129
Drug: Clomipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (mean daily dose, 128.4 mg; range, 100‐150 mg)
Study: 11476129
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean daily dose, 1.3 mg; range, 1‐1.5 mg)
Study: 8489062
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam (0.2 mg/kg)
Study: 8489062
Drug: Sublingual flavored
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual flavored midazolam
Study: 8489062
Drug: Sublingual and
Normalized name: Buprenorphine and Naloxone Sublingual Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual and intranasal midazolam
Study: 3687999
Drug: Suspension
Normalized name: Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: 3687999
Drug: Tablet and
Normalized name: TABLET AND CAPSULE, DOSE PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and Suspension
Study: 28940805
Drug: Naloxone-on-release pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone-on-release pack containing a single 'rescue' injection of naloxone
Study: 25270084
Drug: Artificial dermis
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial dermis (Matriderm) applied in combination with a split-thickness autograft
Study: 22921098
Drug: Intravasation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravasation of distension fluid > 1000 mL
Study: 18672538
Drug: Standard triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple-drug therapy (LPV/r plus zidovudine/lamivudine)
Study: 12586507
Drug: Colon-targeted tablets
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon-targeted tablets of mebendazole (50 mg)
Study: 12586507
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablets of mebendazole (50 mg)
Study: 1387246
Drug: Ondansetron 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.04 mg/kg to 0.35 mg/kg
Study: 1387246
Drug: Ondansetron 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.01 mg/kg to 0.48 mg/kg
Study: 3863469
Drug: Mianserin 20-60
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20-60 mg
Study: 3863469
Drug: Imipramine 75-150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 75-150 mg
Study: 26666876
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg for 18 months
Study: 18785581
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IT) group
Study: 18785581
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (RT) group
Study: 16415711
Drug: Mirtazapine orally
Normalized name: Mirtazapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine orally disintegrating tablets (ODT) 45 mg OD
Study: 16415711
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release (XR) 225 mg OD
Study: 8867517
Drug: Diethylpropion 25
Normalized name: diethylpropion 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylpropion 25 mg
Study: 8867517
Drug: Diethylpropion 50
Normalized name: diethylpropion 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylpropion 50 mg
Study: 8867517
Drug: Diethylpropion 75
Normalized name: diethylpropion 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylpropion 75 mg
Study: 22533981
Drug: ONO‐5334 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 30 mg
Study: 22533981
Drug: ONO‐5334 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 100 mg
Study: 22533981
Drug: ONO‐5334 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 300 mg
Study: 22533981
Drug: ONO‐5334 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 600 mg
Study: 11873074
Drug: High-titered ALVAC-HIV
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titered ALVAC-HIV vCP205 vaccine
Study: 6633272
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg daily for 4 months)
Study: 6633272
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet daily for 4 months)
Study: 6633272
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 and lynestrenol (1 mg daily during days 91-100)
Study: 6633272
Drug: Withdrawal bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal bleeding after cessation of treatment
Study: 31033162
Drug: Robust skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robust skin care regimen including chemical peels and antioxidant formulations (Group B)
Study: 30028657
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily with enzalutamide
Study: 27265347
Drug: S-1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks for up to four cycles)
Study: 27265347
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2, intravenously administered on days 1, 8, and 15, every 4 weeks for up to six cycles)
Study: 20354539
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with whole-brain radiation therapy (WBRT)
Study: 18228689
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments for orphan diseases
Study: 12468561
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ascorbic acid daily by mouth
Study: 9709941
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral magnesium (15 mmol Mg) supplementation
Study: 2122926
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean daily dose, 293 mg)
Study: 2122926
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean daily dose, 350 mg)
Study: 2122926
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean daily dose, 79 mg)
Study: 21816845
Drug: 200-mg-bid celecoxib
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg-bid celecoxib
Study: 21816845
Drug: 400-mg-bid celecoxib
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mg-bid celecoxib
Study: 18093337
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) plus pill placebo
Study: 15075550
Drug: AIDSVAX B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX B/E HIV vaccine trial
Study: 11594256
Drug: Incision or
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision or aspiration with antibiotics
Study: 2974776
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg daily)
Study: 25636180
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1,200 mg/day of eicosapentaenoic acid and 600 mg/day of docosahexaenoic acid for 90 days)
Study: 23201326
Drug: Tibolone (2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5mg daily)
Study: 20568387
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) injections
Study: 18586644
Drug: Fish sauce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish sauce containing 10 mg of iron (either as NaFe‐EDTA or FeSO4+citrate)
Study: 12668405
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) and supportive psychotherapy (SPT) combined
Study: 1526089
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nizatidine twice daily
Study: 1526089
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine at bedtime
Study: 29750261
Drug: Sequential intensity-modulated
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intensity-modulated radiation therapy
Study: 24906029
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg/day, titrated to 30 mg/day and 60 mg/day)
Study: 22502793
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injections plus physical therapy (PT)
Study: 18614875
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum alpha-fetoprotein level (<5.0 ng/ml)